Dianthus Therapeutics (NASDAQ:DNTH) Trading 8% Higher – Here’s Why

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) was up 8% on Wednesday . The company traded as high as $24.41 and last traded at $24.08. Approximately 93,002 shares changed hands during mid-day trading, a decline of 63% from the average daily volume of 251,486 shares. The stock had previously closed at $22.29.

Analyst Ratings Changes

Several analysts have commented on DNTH shares. Oppenheimer raised their price objective on Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a report on Monday, November 11th. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research note on Monday, November 11th. Raymond James upgraded shares of Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. Finally, TD Cowen assumed coverage on shares of Dianthus Therapeutics in a research report on Friday, December 20th. They issued a “buy” rating on the stock. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $46.43.

Dianthus Therapeutics Price Performance

The stock has a market capitalization of $733.16 million, a PE ratio of -9.91 and a beta of 1.72. The company’s 50 day moving average price is $23.06 and its two-hundred day moving average price is $25.88.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The business had revenue of $2.17 million during the quarter, compared to analysts’ expectations of $1.07 million. Analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Institutional Trading of Dianthus Therapeutics

Large investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC increased its stake in Dianthus Therapeutics by 9.2% during the fourth quarter. SG Americas Securities LLC now owns 9,653 shares of the company’s stock worth $210,000 after acquiring an additional 814 shares during the last quarter. Quest Partners LLC increased its position in shares of Dianthus Therapeutics by 112,400.0% during the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock worth $31,000 after purchasing an additional 1,124 shares during the last quarter. R Squared Ltd purchased a new stake in Dianthus Therapeutics in the 4th quarter valued at about $26,000. Rhumbline Advisers lifted its position in Dianthus Therapeutics by 3.8% in the fourth quarter. Rhumbline Advisers now owns 35,933 shares of the company’s stock valued at $783,000 after buying an additional 1,316 shares during the last quarter. Finally, KBC Group NV purchased a new position in Dianthus Therapeutics during the fourth quarter worth about $35,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.